Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Patent
1996-03-14
2000-07-04
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
4242831, 53038823, 530399, 435 63, 514573, 549422, 554117, 554118, 554214, 560120, A61K 39395, C07C 59147, A01N 3708, C07K 1600
Patent
active
06083501&
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung, as well as to model animals of these diseases.
BACKGROUND ART
Pulmonary heart disease (cor pulmonale) is the state showing right ventricular pressure load or dysfunction of right ventricle by increase in pulmonary vascular resistance caused by diseases of lung parenchyma, pulmonary vascular diseases or extrapulmonary diseases which cause alveolar hypoventilation. Based on clinical progress and pathologic state, pulmonary heart disease is classified into three groups, that is, acute pulmonary heart, subacute pulmonary heart and chronic pulmonary heart, and the type of primary diseases of the three groups are different from each other. The representative cause of acute pulmonary heart is pulmonary thromboembolism in which right ventricle is prominently dilated without the time of presenting right ventricular hypertrophy, followed by right heart failure. The causes of subacute pulmonary heart disease include multiple or recurrent lung embolism, but its pathologic state is similar to that of acute pulmonary heart disease. The causes of chronic pulmonary heart disease include chronic occlusive pulmonary disease and pulmonary hypertension. Chronic pulmonary heart disease accompanies hyperplasia of right ventricular heart muscle, respiratory difficulty when moving, cardiopalmus and edema, and its prognosis is bad. Fibrinoid formation or thrombus formation in the lung plays a pivotal role in development of these pathological stage.
Current therapeutic methods for treating pulmonary heart disease are based on therapy and control of the primary diseases. There is no effective etiotropic methods and only nosotropic treatment is performed.
As for the model animals used for clarifying the pathologic state and for studying effective therapeutic method or the like, monocrotaline-treated rat models were employed as the model animal for pulmonary hypertension. This model is pathologically characterized mainly by hyperplasia of tunica media of muscular pulmonary artery, muscularization of pulmonary arteriole and hyperplasia of intraalveolar septa.
However, in the conventional monocrotaline-rat model animal, fibrinoid formation and thrombus formation in the lung are scarcely observed in the development of the diseased state, and the monocrotaline-rat model animal is positioned as a model of the so called secondary pulmonary hypertension in which pulmonary hypertension and interstitial pneumonia are complicated. Thus, the monocrotaline-rat model is insufficient for clarifying the pathologic state of testing pulmonary heart and for studying a therapeutic method of testing pulmonary heart depending on the severity of the disease. There is no promising therapeutic method for pulmonary heart.
DISCLOSURE OF THE INVENTION
An object of the present invention is to provide a drug for the prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the vascular system of the lung, such as pulmonary heart disease. Another object of the present invention is to provide a model animal for in the pulmonary heart disease caused by fibrinoid formation or thrombus formation in blood circulation of the lung.
The present inventors discovered that by administering interleukin 6 (hereinafter also referred to as "IL-6") to rats, formation of fibrinoid or thrombus in the lung is caused to develop pulmonary heart disease and that prevention and therapy of the diseases caused by fibrinoid formation or thrombus formation in the lung can be attained by administering an IL-6 inhibitor, thereby completing the present invention.
That is, the present invention provides a drug for preventing and treating diseases caused by fibrinoid formation or thrombus formation in the lung, which comprises an inhibitor of interleukin 6 as an effective ingredient. The present invention also provides a model rat of the diseases caused by fibrinoid formation or thrombus formation in
REFERENCES:
patent: 5135955 (1992-08-01), Campbell et al.
patent: 5162361 (1992-11-01), Rosenthal
patent: 5271931 (1993-12-01), Lotz
patent: 5300292 (1994-04-01), Ulich
patent: 5376368 (1994-12-01), Ulich
van der Poll, T. et al. J. Exp. Med; 179: 1253-1259, 1994.
Norioka, K. et al. Auto Immunity, 7: 41-50, 1990.
Wakefield, Venous Thrombus Arteriosclerosis Thrombosisal Vascular Bio 15, 2, 1995 258-268.
Waldman, T Science vol. 252 Jun. 21, 1991 pp. 1657-1662.
Hams, Tibtech Therapeutic Abs Coming of age Feb. 1993 vol. 11 pp. 42-44.
Samad, F et al Stimulation of Chick hepatocyte fibronectin production by fibroblast-conditioned medium Biochim Biophys ACTA 1181 (3) 1993 207-213.
Ida Nobuo
Ida Nobutaka
Kasukawa Reiji
Kojima Katsuaki
Miyata Masayuki
Bansal Geetha P.
Hutzell Paula K.
Toray Industries Inc.
LandOfFree
Drug for prevention and therapy of diseases caused by fibrinoid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug for prevention and therapy of diseases caused by fibrinoid , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug for prevention and therapy of diseases caused by fibrinoid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1483372